

1 **Supporting Information for:**

2

3 **Computational/experimental evaluation of liver metastasis post hepatic injury:**
4 **interactions with macrophages and transitional ECM**

5

6 Shanice V. Hudson^{1,2}, Hunter A. Miller², Grace E. Mahlbacher², Douglas Saforo^{1,4}, Levi
7 J. Beverly^{1,2,4}, Gavin E. Arteel^{3,§}, Hermann B. Frieboes^{1,2,4,§*}

8

9 ¹Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY
10 40202, USA

11 ²Department of Bioengineering, University of Louisville, KY 40208, USA

12 ³Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition,
13 University of Pittsburgh, Pittsburgh, PA 15261, USA

14 ⁴James Graham Brown Cancer Center, University of Louisville, KY 40202, USA

15 [§]Joint senior authorship

16

17

18

19 Differentiation and Movement of Macrophages

20 Following the description in ¹, as naïve macrophages $M\phi$ extravasate from the
21 vasculature into the tumor tissue, they come into contact with proteins in the tumor
22 microenvironment that influence their differentiation. The respective differentiation rate
23 R_i depends on the size of the interval that a randomly generated number may fall into;
24 hence, the differentiation probabilities depend on the protein concentrations:

$$\begin{aligned} 25 \quad R_{M1} &\propto k_{M1} \cdot C_{M1f} \\ R_{M2} &\propto k_{M2} \cdot C_{M2f} \end{aligned} \quad \text{[Equation S1]}$$

26 where k_{M1}, k_{M2} are intensity coefficients tuned to reflect the relative prevalence of M1 or
27 M2 differentiating monocytes infiltrating the tumor (**S4 Table**), C_{M1f} and C_{M2f} are the
28 local concentrations of cytokines and other factors favorable to M1 or M2,
29 differentiation, respectively, released by the viable (proliferating or hypoxic) tumor
30 regions. Here, TNF- α and TGF β 1, are taken as representative tumor microenvironment
31 molecules that influence polarization towards an M1 ² and M2 ³ phenotype, respectively
32 (**S2 Table**).

33
34 As described in ¹, macrophages migrate through the tumor interstitium along gradients
35 of oxygen, pressure, and chemoattractants. Movement can be in one of four directions
36 in the 2D computational grid. The probability of movement in the $x+1$ direction is:

$$37 \quad P_{x+1} = (M_O \cdot \Delta O_{x+1} + M_P \cdot \Delta P_{x+1} + M_C \cdot \Delta Chemo_{x+1}) \quad \text{[Equation S2]}$$

38 where M_O, M_P and M_C are intensity coefficients representing the influence of oxygen
39 concentration, pressure, and chemoattractant on macrophage movement (**S4 Table**),
40 and $\Delta O_{x+1}, \Delta P_{x+1}$ and $\Delta Chemo_{x+1}$ are the difference in concentration of the factor of

- 41 interest from the current point to the direction in question. The same calculations are
- 42 made for the remaining three directions in the 2D grid.

43 **Supplementary Tables**

44

45 **S1 Table.** Values for model main parameters (from ¹). All other tumor parameters are as
 46 in ⁴. *Non-dimensionalized by O₂ diffusivity (1×10⁻⁵ cm²s⁻¹ ⁵).

47

| Parameter | Value | Reference |
|---|--------|---|
| Hypoxic tissue threshold (primary tumors) | 0.5750 | ⁶ |
| Necrotic tissue threshold (primary tumors) | 0.5700 | ⁶ |
| Host vessel grid (primary tumors) | 8x8 | ⁶ |
| Hypoxic tissue threshold (metastatic tumors) | 0.5750 | ⁷ |
| Necrotic tissue threshold (metastatic tumors) | 0.5325 | ⁷ |
| Host vessel grid (metastatic tumors) | 19x19 | ⁷ |
| O ₂ diffusivity | 1* | ⁴ |
| O ₂ vascular transfer rate | 5* | ⁴ |
| Normoxic O ₂ uptake rate | 1.5* | ⁴ |
| Hypoxic O ₂ uptake rate | 1.3* | ⁴ |
| Microenvironment O ₂ uptake rate | 0.12* | ⁴ |
| O ₂ decay rate | 0.35* | ⁴ |
| cECM production constant | 5 | Calibrated from matrisome analysis ⁸ |
| cECM degradation constant | 1 | Calibrated from matrisome analysis ⁸ |
| tECM production constant | 10 | Calibrated from matrisome analysis ⁸ |
| tECM degradation constant | 0.1 | Calibrated from matrisome analysis ⁸ |

48

49

50 **S2 Table.** Macrophage-associated cytokines simulated in the tumor microenvironment
51 (adapted from ¹). *Diffusivity assumed similar to IL-10 in ¹.

52

| Cytokine | Associated with: | Source | MW (kDa) | Diffusivity (as fraction of TAF diffusivity) |
|-----------------|-------------------------|--|-----------------|---|
| TNF- α | M1 polarization | Hypoxic and proliferating tumor tissue | 17 | 3.7606* |
| TGF- β | M2 polarization | Hypoxic and proliferating tumor tissue | 13 | 3.7606* |
| NO | Local tumor necrosis | M1 | 0.03 | 0 |

53

54

55 **S3 Table.** Model rate parameters for macrophage-associated cytokines adapted from ¹.
 56 Washout and decay rates are generically applied to all cytokines, C (based on
 57 proteomic analysis in ⁹). *Value non-dimensionalized by O₂ diffusivity (1 x 10⁻⁵ cm² s⁻¹ ⁵).
 58 **Value rescaled by the production rate of VEGF-A (VEGF-165) protein.

59

| Parameter | Function | Value |
|---|---|--------|
| $\bar{\lambda}_{circulation}^C$ | Wash-out rate into vasculature | 0.006* |
| $\bar{\lambda}_{decay}^C$ | Decay rate | 0.001* |
| $D_{TNF-\alpha}$ | Diffusivity for TNF- α | 0.005* |
| $D_{TGF-\beta}$ | Diffusivity for TGF- β | 0.005* |
| $\bar{\lambda}_{production}^{TNF-\alpha}$ | Production rate of TNF- α (primary tumors) | 1.0** |
| $\bar{\lambda}_{production}^{TNF-\alpha}$ | Production rate of TNF- α (metastatic tumors) | 10.0** |
| $\bar{\lambda}_{production}^{TGF-\beta}$ | Production rate of TGF- β (primary tumors) | 1.0** |
| $\bar{\lambda}_{production}^{TGF-\beta}$ | Production rate of TGF- β (metastatic tumors) | 1.0** |

60

61


62 **S4 Table.** Characteristics of macrophage model parameters (adapted ¹). *Value non-
 63 dimensionalized by O₂ diffusivity (1 x 10⁻⁵ cm² s⁻¹ 5).

64

| Parameter | Description | Value | Reference |
|---|--|---------|-----------------------------------|
| <i>Parameters Related to Tumor Growth</i> | | | |
| λ_M | Tumor native proliferation rate (day ⁻¹) | 0.5 | ⁷ |
| λ_{OL} | Recovery rate of quiescent oxygen level | 0.05* | ¹⁰ |
| λ_{OT} | M2 induced lowering viable O ₂ threshold rate | 200 /s | ¹⁰ |
| λ_{rec} | Recovery rate of λ_{M2} to zero | 0.1* | ¹⁰ |
| λ_F | M2 induced proliferation rate | 1000 /s | ¹⁰ |
| λ_{NO} | M1 nitric oxide induced death rate | 3 /s | ¹¹ |
| G_N | Cell degradation rate in necrotic region | 0.3* | ⁷ |
| <i>Differentiation Scaling Coefficients</i> | | | |
| k_{M1} | M1 macrophage (primary tumors) | 20 | ¹⁰ |
| k_{M2} | M2 macrophage (primary tumors) | 20 | ¹⁰ |
| k_{M1} | M1 macrophage (metastatic tumors) | 200 | Scaled based on experimental data |
| k_{M2} | M2 macrophage (metastatic tumors) | 20 | 28 |
| <i>Movement Scaling Coefficients</i> | | | |
| M_O | Effect of oxygen on macrophage movement | 1000 | ⁷ |
| M_P | Effect of oxygen on macrophage movement | 350 | ⁷ |
| M_C | Chemotactic macrophage movement | 500 | ⁷ |

65

66



68

69 **S1 Figure. Decellularization of liver tissue.**

70 Gross pathology and histological analysis of decellularized liver tissue. (A) Tissues at
71 each step of decellularization; at 48h, incubation in SDS solution yields translucent
72 tissue “ghost” prepared for lyophilization. (B) Histological analysis of decellularized liver
73 tissues. Top row shows control livers; bottom row represents decellularized samples. In
74 the first column, Sirius Red/Fast Green collagen staining shows normal tissue in top
75 row, with red staining of collagen, reticulin fibers, and basement membrane, and green

76 staining of non-collagenous proteins, while the decellularized sample in bottom row
77 shows only collagenous material remaining. The second column shows H&E stain of
78 normal tissue (top), and denucleation of acellular samples in the bottom row. The third
79 column shows Trichrome stain of normal tissue (top), with nuclei stained in black,
80 cytoplasm stained red, and collagen in blue; the acellular sample (bottom) shows
81 removal of nuclei and cytoplasm, with retention of collagen in blue.

82

83

84

Reference List

85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116

117

118

- 1 Mahlbacher, G., Curtis, L. T., Lowengrub, J. & Frieboes, H. B. Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment. *Journal for immunotherapy of cancer* **6**, 10, doi:10.1186/s40425-017-0313-7 (2018).
- 2 Ruytinx, P., Proost, P., Van Damme, J. & Struyf, S. Chemokine-Induced Macrophage Polarization in Inflammatory Conditions. *Frontiers in immunology* **9**, 1930, doi:10.3389/fimmu.2018.01930 (2018).
- 3 Zhang, F. *et al.* TGF-beta induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype. *Oncotarget* **7**, 52294-52306, doi:10.18632/oncotarget.10561 (2016).
- 4 Wu, M. *et al.* The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. *Journal of theoretical biology* **320**, 131-151, doi:10.1016/j.jtbi.2012.11.031 (2013).
- 5 Nugent, L. J. & Jain, R. K. Extravascular diffusion in normal and neoplastic tissues. *Cancer research* **44**, 238-244 (1984).
- 6 van de Ven, A. L. *et al.* Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. *AIP advances* **2**, 11208, doi:10.1063/1.3699060 (2012).
- 7 Leonard, F. *et al.* Enhanced performance of macrophage-encapsulated nanoparticle albumin-bound-paclitaxel in hypo-perfused cancer lesions. *Nanoscale* **8**, 12544-12552, doi:10.1039/c5nr07796f (2016).
- 8 Massey, V. L. *et al.* The hepatic "matrisome" responds dynamically to injury: Characterization of transitional changes to the extracellular matrix in mice. *Hepatology (Baltimore, Md.)* **65**, 969-982, doi:10.1002/hep.28918 (2017).
- 9 Frieboes, H. B., Curtis, L. T., Wu, M., Kani, K. & Mallick, P. Simulation of the Protein-Shedding Kinetics of a Fully Vascularized Tumor. *Cancer informatics* **14**, 163-175, doi:10.4137/cin.S35374 (2015).
- 10 Leonard, F. *et al.* Macrophage Polarization Contributes to the Anti-Tumoral Efficacy of Mesoporous Nanovectors Loaded with Albumin-Bound Paclitaxel. *Frontiers in immunology* **8**, 693, doi:10.3389/fimmu.2017.00693 (2017).
- 11 Yuan, A. *et al.* Opposite Effects of M1 and M2 Macrophage Subtypes on Lung Cancer Progression. *Scientific reports* **5**, 14273, doi:10.1038/srep14273 (2015).